Erectile dysfunction is associated with low total serum testosterone levels and impaired flow-mediated vasodilation in intermediate risk men according to the framingham risk score

Atherosclerosis

Volumn 238, Issue 2, 2015, Pages 415-419

  Novo, Salvatore ^a   Iacona, Rosanna ^a   Bonomo, Vito ^a   Evola, Vincenzo ^a   Corrado, Egle ^a   Di Piazza, Mariaconcetta ^a   Novo, Giuseppina ^a   Pavone, Carlo ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Endothelial function; Erectile dysfunction; Flow mediated vasodilation; Serum testosterone levels

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM ANTAGONIST; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; TESTOSTERONE; BIOLOGICAL MARKER;

ADULT; ARTICLE; BODY MASS; BRACHIAL ARTERY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ECHOGRAPHY; ERECTILE DYSFUNCTION; FRAMINGHAM RISK SCORE; HIP CIRCUMFERENCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SMOKING; TESTOSTERONE BLOOD LEVEL; VASODILATATION; WAIST CIRCUMFERENCE; AGED; BLOOD; BLOOD FLOW; CHI SQUARE DISTRIBUTION; DEFICIENCY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; RISK; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRACHIAL ARTERY; CHI-SQUARE DISTRIBUTION; ERECTILE DYSFUNCTION; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERIPHERAL ARTERIAL DISEASE; REGIONAL BLOOD FLOW; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TESTOSTERONE; VASODILATION;

EID: 84920128324     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.12.007     Document Type: Article

References (42)

1. Lojanapiwat B., Weerusawin T., Kuanprasert S. Erectile dysfunction as a sentinel marker of endothelial dysfunction disease. Singap. Med. J. 2009, 50:698-701.
2. Miner M. Engaging patients in cardiovascular disease risk reduction: from empathy to erectile dysfunction. Am. J. Lifestyle Med. 2007, 1:41-43.
3. Jackson G. Erectile dysfunction: a marker of silent coronary artery disease. Eur. Heart J. 2006, 27:2613-2614.
4. Vlachopoulos C., Aznaouridis K., Ioakeimidis N., Rokkas K., Vasiliadou C., Alexopoulos N., et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur. Heart J. 2006, 27:2640-2648.
5. Pavone C., Curto F., Anello G., Serretta V., Almasio P.L., Pavone-Macaluso M. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. J.Urol. 2008, 179(5 Suppl.l):S92-S94.
6. Mascitelli L., Pezzetta F. Erectile dysfunction and incidence of cardiovascular disease. J.Am. Med. Assoc. 2006, 295:1998-1999.
7. Corrado E., Rizzo M., Coppola G., Fattouch K., Novo G., Marturana I., et al. An update on the role of markers of inflammation in atherosclerosis. J.Atheroscler. Thromb. 2010, 17:1-11.
8. Corrado E., Muratori I., Tantillo R., Contorno F., Coppola G., Strano A., et al. Relationship between endothelial dysfunction, intima media thickness and cardiovascular risk factors in asymptomatic subjects. Int. Angiol. 2005, 24:52-58.
9. Kaufman J.M., Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 2005, 26:833-876.
10. Yeap B.B. Androgens and cardiovascular disease. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17:269-276.
11. Yeap B.B., Hyde Z., Almeida O.P., et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J.Clin. Endocrinol. Metab. 2009, 94:2353-2359.
12. Haring R., Volzke H., Steveling A., Krebs A., Felix S.B., Schofl C., et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur. Heart J. 2010, 31:1494-1501.
13. Khaw K.T., Dowsett M., Folkerd E., Bingham S., Wareham N., Luben R., et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into Cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 2007, 116:2694-2701.
14. Surampudi P.N., Wang C., Swerdloff R. Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int. J. Endocrinol. 2012, 2012:625434.
15. Shabsigh R., Katz M., Yan G., Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am. J. Cardiol. 2005, 96:67M-72M.
16. Nettleship J.E., Jones R.D., Channer K.S., Jones T.H. Testosterone and coronary artery disease. Front. Horm. Res. 2009, 37:91-107.
17. Muller M., van den Beld A.W., Bots M.L., Grobbee D.E., Lamberts S.W.J., van der Schouw Y.T. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 2004, 109:2074-2079.
18. Tivesten Å., Mellström D., Jutberger H., Fagerberg B., Lernfelt B., Orwoll E., et al. Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS study in Sweden. J.Am. Coll. Cardiol. 2007, 50:1070-1076.
19. Hak A.E., Witteman J.C.M., de Jong F.H., Geerlings M.I., Hofman A., Pols H.A.P. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam Study. J.Clin. Endocrinol. Metab. 2002, 87:3632-3639.
20. Shores M.M., Matsumoto A.M., Sloan K.L., Kivlahan D.R. Low serum testosterone and mortality in male veterans. Arch. Int. Med. 2006, 166:1660-1665.
21. Laughlin G.A., Barrett-Connor E., Bergstrom J. Low serum testosterone and mortality in older men. J.Clin. Endocrinol. Metab. 2008, 93:68-75.
22. Malkin C.J., Pugh P.J., Morris P.D., Asif S., Jones T.H., Channer K.S. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010, 96:1821-1825.
23. Akishita M., Hashimoto M., Ohike Y., Ogawa S., Iijima K., Eto M., et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens. Res. 2007, 30:1029-1034.
24. Empen K., Lorbeer R., Dörr M., Haring R., Nauck M., Gläser S., et al. Association of testosterone levels with endothelial function in men: results from a population-based study. Arterioscler. Thromb. Vasc. Biol. 2012, 32:481-486.
25. Rhoden E.L., Telöken C., Sogari P.R., Vargas Souto C.A. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int. J. Impot. Res. 2002, 14:245-250.
26. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J.Am. Coll. Cardiol. 2002, 39:257-265.
27. Thijssen D.H., Black M.A., Pyke K.E., Padilla J., Atkinson G., Harris R.A., et al. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am. J. Physiol. Heart Circ. Physiol. 2011, 300(Suppl.l):H2-H12.
28. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J.Hypertens. 2013, 31:1281-1357.
29. Gandaglia G., Briganti A., Jackson G., Kloner R.A., Montorsi F., Montorsi P., et al. Asystematic review of the association between erectile dysfunction and cardiovascular disease. Eur. Urol. 2014 May, 65(5):968-978. [E-pub ahead of print]. 10.1016/j.eururo.2013.08.023.
30. Becker A.J., Uckert S., Tsikas D., Noack H., Stief C.G., Frölich J.C., et al. Determination of nitric oxide metabolites by means of the Griess assay and gas chromatography-mass spectrometry in the cavernous and systemic blood of healthy males and patients with erectile dysfunction during different functional conditions of the penis. Urol. Res. 2000, 28:364-369.
31. Cunningham G.R., Toma S.M. Why is androgen replacement in males controversial?. J.Clin. Endocrinol. Metab. 2011, 96:38-52.
32. Ong P.J., Patrizi G., Chong W.C., Webb C.M., Hayward C.S., Collins P. Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am. J. Cardiol. 2000, 85:269-272.
33. Webb C.M., McNeill J.G., Hayward C.S., de Zeigler D., Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999, 100:1690-1696.
34. Orshal J.M., Khalil R.A. Gender, sex hormones, and vascular tone. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 286:233-249.
35. Herring M.J., Oskui P.M., Hale S.L., Kloner R.A. Testosterone and the cardiovascular system: a comprehensive review of the basic science literature. J.Am. Heart Assoc. 2013, 2:e000271.
36. Bernini G., Versari D., Moretti A., Virdis A., Ghiadoni L., Bardini M., et al. Vascular reactivity in congenital hypogonadal men before and after testosterone replacement therapy. J.Clin. Endocrinol. Metab. 2006, 91:1691-1697.
37. Sader M.A., Griffiths K.A., Skilton M.R., Wishart S.M., Handelsman D.J., Celermajer D.S. Physiological testosterone replacement and arterial endothelial function in men. Clin. Endocrinol. 2003, 59:62-67.
38. Zitzmann M., Brune M., Nieschlag E. Vascular reactivity in hypogonadal men is reduced by androgen substitution. J.Clin. Endocrinol. Metab. 2002, 87:5030-5037.
39. Ebenbichler C.F., Sturm W., Ganzer H., Bodner J., Mangweth B., Ritsch A., et al. Flow-mediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids. Atherosclerosis 2001, 158:483-490.
40. Sader M.A., Griffiths K.A., McCredie R.J., Handelsman D.J., Celermajer D.S. Androgenic anabolic steroids and arterial structure and function in male bodybuilders. J.Am. Coll. Cardiol. 2001, 37:224-230.
41. Leifke E., Kinzel M., Tsikas D., Gooren L., Frölich J.C., Brabant G. Effects of normalization of plasma testosterone levels in hypogonadal men on plasma levels and urinary excretion of asymmetric dimethylarginine (ADMA). Horm. Metab. Res. 2008, 40:56-59.
42. Inoue T., Matsuoka H., Higashi Y., Ueda S., Sata M., Shimada K., et al. Flow-mediated vasodilation as a diagnostic modality for vascular failure. Hypertens. Res. 2008, 31:2105-2113.